Login / Signup

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma.

Atul GuptaIsabelle PouliquenDaren AustinRobert G PriceRodger KempsfordJonathan SteinfeldEric S BradfordSteven W Yancey
Published in: Pediatric pulmonology (2019)
In children 6 to 11 years-of-age with severe eosinophilic asthma, mepolizumab SC 40 or 100 mg provided bodyweight-adjusted drug exposure within twofold of target adult exposure as well as marked reductions to blood eosinophil counts similar to adults, and although not designed to evaluate efficacy outcomes, demonstrated a positive clinical profile.
Keyphrases
  • chronic obstructive pulmonary disease
  • lung function
  • chronic rhinosinusitis
  • early onset
  • allergic rhinitis
  • young adults
  • drug induced
  • peripheral blood
  • metabolic syndrome
  • insulin resistance
  • adverse drug